Report Code: 11674 | Available Format: PDF | Pages: 329
Ecosystem of Healthcare Industry Research Report: By Disease Type, Payment Mechanism, Diagnostic Equipment Type, In-vitro Diagnostic Technology, Channel, Hospital Bed Capacity, Payer Type, Provider Type, Care Pathway Stage, Disease Stage Type, Regional Insight (U.S., U.K, France, Germany, China, Japan, Singapore) – Growth Prospect and Forecast to 2024
- Report Code: 11674
- Available Format: PDF
- Pages: 329
- Report Description
- Table of Contents
- Market Segmentation
- Request Free Sample
Chapter 1. Research Background
1.1 Research Objectives
1.2 Market Definition
1.3 Research Scope
1.3.1 Market Segmentation by Disease Type
1.3.2 Market Segmentation by Payment Mechanism
1.3.3 Market Segmentation by Diagnostic Equipment Type
1.3.4 Market Segmentation by In-vitro Diagnostic (IVD) Technology
1.3.5 Market Segmentation by Channel
1.3.6 Market Segmentation by Hospital Bed Capacity
1.3.7 Market Segmentation by Payer Type
1.3.8 Market Segmentation by Provider Type
1.3.9 Market Segmentation by Care Pathway Stage
1.3.10 Market Segmentation by Disease Stage
1.3.11 Market Segmentation by Country
1.3.12 Analysis Period
1.4 Key Stakeholders
Chapter 2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.2.1 Breakdown of Primary Research Respondents
2.2.1.1 By country
2.2.1.2 By industry participant
2.2.1.3 By company type
2.3 Market Size Estimation
2.4 Data Triangulation
2.5 Assumptions for the Study
Chapter 3. Executive Summary
Chapter 4. Introduction
4.1 Definition of Market Segments
4.1.1 By Disease Type
4.1.1.1 Cardiovascular and circulatory diseases
4.1.1.2 Neuropsychiatric disorders
4.1.1.3 CRD
4.1.1.4 Diabetes, blood, and endocrine disorders
4.1.1.5 Cancer
4.1.1.6 Chronic liver diseases
4.1.1.7 Musculoskeletal disorders
4.1.1.8 Others
4.1.2 By Payment Mechanism
4.1.2.1 Fee-for-service
4.1.2.2 Self-pay
4.1.2.3 Value-based reimbursement
4.1.3 By Diagnostic Equipment Type
4.1.3.1 X-Ray
4.1.3.2 MRI
4.1.3.3 Ultrasound
4.1.3.4 CT
4.1.3.5 Mammography
4.1.3.6 Endoscopes
4.1.3.7 Others
4.1.4 By IVD Technology
4.1.4.1 Immunoassay/immunochemistry
4.1.4.2 Clinical chemistry
4.1.4.3 Molecular diagnostics
4.1.4.4 Microbiology
4.1.4.5 Hematology
4.1.4.6 Urinalysis
4.1.4.7 Others
4.1.5 By Channel
4.1.5.1 Non-profit
4.1.5.2 For-profit
4.1.5.3 State/local
4.1.5.4 Others
4.1.6 By Hospital Bed Capacity
4.1.6.1 <100
4.1.6.2 100-199
4.1.6.3 200-499
4.1.6.4 >=500
4.1.7 By Payer Type
4.1.7.1 Medicare
4.1.7.2 Medicaid
4.1.7.3 Private payers
4.1.7.4 Others
4.1.8 By Provider Type
4.1.8.1 Primary care
4.1.8.2 Nursing care
4.1.8.3 Specialty care
4.1.8.3.1 Endocrinology
4.1.8.3.2 Gastroenterology
4.1.8.3.3 Hematology
4.1.8.3.4 Neurology
4.1.8.3.5 Oncology
4.1.8.3.6 Urology
4.1.8.3.7 Cardiology
4.1.8.3.8 Gynecology
4.1.8.3.9 Others
4.1.9 By Care Pathway Stage
4.1.9.1 Primary prevention
4.1.9.2 Early management
4.1.9.3 Treatment
4.1.9.4 Prevention and management of complications
4.1.10 By Disease Stage
4.1.10.1 Chronic
4.1.10.2 Acute
4.2 Market Dynamics
4.2.1 Trends
4.2.1.1 Increasing number of collaborations and partnerships
4.2.1.2 Rise in number of mergers and acquisitions
4.2.1.3 Increasing number of product launches
4.2.1.4 Integration of biosensors in healthcare industry
4.2.1.5 Integration of artificial intelligence/machine learning
4.2.2 Drivers
4.2.2.1 Increasing prevalence of chronic diseases
4.2.2.2 Government initiatives and better healthcare infrastructure
4.2.2.3 Increasing GDP and healthcare expenditure
4.2.2.4 Rise in the adoption of healthcare insurance
4.2.2.5 Surge in geriatric population
4.2.2.6 Growing demand of IVD tests
4.2.2.7 Digitalization in healthcare industry
4.2.2.8 Impact analysis of drivers on market forecast
4.2.3 Restraints
4.2.3.1 Stringent regulations
4.2.3.2 High cost of development and management of devices
4.2.3.3 Product recalls
4.2.3.4 Impact analysis of restraints on market forecast
4.3 Porter’s Five Forces Analysis
4.4 Regulatory Overview of Healthcare Industry
4.4.1 U.S.
4.4.1.1 Regulations for pharmaceutical products
4.4.1.2 Regulations for healthcare insurance
4.4.1.3 Regulations for medical devices
4.4.2 Europe
4.4.2.1 Regulations for pharmaceutical products and medical devices
4.4.2.2 Regulations for healthcare insurance
4.4.3 APAC
4.4.3.1 China
4.4.3.1.1 Regulations for pharmaceutical products and medical devices
4.4.3.1.2 Regulations for healthcare insurance
4.4.3.2 Japan
4.4.3.2.1 Regulations for pharmaceutical products and medical devices
4.4.3.2.2 Regulations for healthcare insurance
4.5 PESTLE Analysis
4.6 Pricing Analysis
4.6.1 X-Ray Imaging Systems
4.6.2 MRI Systems
4.6.3 Ultrasound Systems
4.6.4 CT Scanners
4.6.5 Nuclear Imaging Systems
Chapter 5. U.S. Market Size and Forecast
5.1 By Disease Type
5.2 By Payment Mechanism
5.3 By Diagnostic Equipment Type
5.4 By IVD Technology
5.5 By Channel
5.6 By Hospital Bed Capacity
5.7 By Payer Type
5.8 By Provider Type
5.8.1 Healthcare Industry for Specialty Care, by Disease Type
5.9 By Care Pathway Stage
5.10 By Disease Stage
Chapter 6. Germany Market Size and Forecast
6.1 By Disease Type
6.2 By Payment Mechanism
6.3 By Diagnostic Equipment Type
6.4 By IVD Technology
6.5 By Channel
6.6 By Hospital Bed Capacity
6.7 By Provider Type
6.7.1 Healthcare Industry for Specialty Care, by Disease Type
6.8 By Care Pathway Stage
6.9 By Disease Stage
Chapter 7. U.K. Market Size and Forecast
7.1 By Disease Type
7.2 By Payment Mechanism
7.3 By Diagnostic Equipment Type
7.4 By IVD Technology
7.5 By Channel
7.6 By Hospital Bed Capacity
7.7 By Provider Type
7.7.1 Healthcare Industry for Specialty Care, by Disease Type
7.8 By Care Pathway Stage
7.9 By Disease Stage
Chapter 8. France Market Size and Forecast
8.1 By Disease Type
8.2 By Payment Mechanism
8.3 By Diagnostic Equipment Type
8.4 By IVD Technology
8.5 By Channel
8.6 By Hospital Bed Capacity
8.7 By Provider Type
8.7.1 Healthcare Industry for Specialty Care, by Disease Type
8.8 By Care Pathway Stage
8.9 By Disease Stage
Chapter 9. China Market Size and Forecast
9.1 By Disease Type
9.2 By Payment Mechanism
9.3 By Diagnostic Equipment Type
9.4 By IVD Technology
9.5 By Channel
9.6 By Hospital Bed Capacity
9.7 By Provider Type
9.7.1 Healthcare Industry for Specialty Care, by Disease Type
9.8 By Care Pathway Stage
9.9 By Disease Stage
Chapter 10. Japan Market Size and Forecast
10.1 By Disease Type
10.2 By Payment Mechanism
10.3 By Diagnostic Equipment Type
10.4 By IVD Technology
10.5 By Channel
10.6 By Hospital Bed Capacity
10.7 By Provider Type
10.7.1 Healthcare Industry for Specialty Care, by Disease Type
10.8 By Care Pathway Stage
10.9 By Disease Stage
Chapter 11. Singapore Market Size and Forecast
11.1 By Disease Type
11.2 By Payment Mechanism
11.3 By Diagnostic Equipment Type
11.4 By IVD Technology
11.5 By Channel
11.6 By Hospital Bed Capacity
11.7 By Provider Type
11.7.1 Healthcare Industry for Specialty Care, by Disease Type
11.8 By Care Pathway Stage
11.9 By Disease Stage
Chapter 12. Competitive Landscape
12.1 Market Share Analysis
12.1.1 Diagnostic Imaging Market
12.1.2 IVD Market
12.2 Global Strategic Developments of Key Players
12.2.1 Product Launches and Approvals
12.2.2 Collaborations
12.2.3 Acquisitions
Chapter 13. Company Profiles
13.1 Diagnostic Equipment Players
13.1.1 General Electric Company
13.1.1.1 Business overview
13.1.1.2 Product and service offerings
13.1.1.3 Key financial summary
13.1.2 Koninklijke Philips N.V.
13.1.2.1 Business overview
13.1.2.2 Product and service offerings
13.1.2.3 Key financial summary
13.1.3 Siemens AG
13.1.3.1 Business overview
13.1.3.2 Product and service offerings
13.1.3.3 Key financial summary
13.1.4 Canon Medical Systems Corporation
13.1.4.1 Business overview
13.1.4.2 Product and service offerings
13.1.4.3 Key financial summary
13.1.5 Shimadzu Corporation
13.1.5.1 Business overview
13.1.5.2 Product and service offerings
13.1.5.3 Key financial summary
13.1.6 Carestream Health Inc.
13.1.6.1 Business overview
13.1.6.2 Product and service offerings
13.1.7 Esaote S.p.A.
13.1.7.1 Business overview
13.1.7.2 Product and service offerings
13.1.8 FUJIFILM Holdings Corporation
13.1.8.1 Business overview
13.1.8.2 Product and service offerings
13.1.8.3 Key financial summary
13.1.9 Samsung Electronics Co. Ltd.
13.1.9.1 Business overview
13.1.9.2 Product and service offerings
13.1.9.3 Key financial summary
13.1.10 Hologic Inc.
13.1.10.1 Business overview
13.1.10.2 Product and service offerings
13.1.10.3 Key financial summary
13.2 IVD Players
13.2.1 bioMérieux S.A.
13.2.1.1 Business overview
13.2.1.2 Product and service offerings
13.2.1.3 Key financial summary
13.2.2 Bio-Rad Laboratories Inc.
13.2.2.1 Business overview
13.2.2.2 Product and service offerings
13.2.2.3 Key financial summary
13.2.3 Thermo Fisher Scientific Inc.
13.2.3.1 Business overview
13.2.3.2 Product and service offerings
13.2.3.3 Key financial summary
13.2.4 Becton, Dickinson and Company
13.2.4.1 Business overview
13.2.4.2 Product and service offerings
13.2.4.3 Key financial summary
13.2.5 Danaher Corporation
13.2.5.1 Business overview
13.2.5.2 Product and service offerings
13.2.5.3 Key financial summary
13.2.6 Abbott Laboratories
13.2.6.1 Business overview
13.2.6.2 Product and service offerings
13.2.6.3 Key financial summary
13.2.7 Siemens AG
13.2.7.1 Business overview
13.2.7.2 Product and service offerings
13.2.7.3 Key financial summary
13.2.8 QIAGEN N.V.
13.2.8.1 Business overview
13.2.8.2 Product and service offerings
13.2.8.3 Key financial summary
13.2.9 DiaSorin S.p.A.
13.2.9.1 Business overview
13.2.9.2 Product and Service Offerings
13.2.9.3 Key financial summary
13.2.10 Ortho-Clinical Diagnostics Inc.
13.2.10.1 Business overview
13.2.10.2 Product and service offerings
13.2.11 F. Hoffmann-La Roche Ltd.
13.2.11.1 Business overview
13.2.11.2 Product and service offerings
13.2.11.3 Key financial summary
13.2.12 Agilent Technologies Inc.
13.2.12.1 Business overview
13.2.12.2 Product and service offerings
13.2.12.3 Key financial summary
Chapter 14. Appendix
14.1 Abbreviations
14.2 Sources and References
14.3 Related Reports
LIST OF TABLES
TABLE 1 ANALYSIS PERIOD OF THE STUDY
TABLE 2 DRIVERS FOR THE MARKET: IMPACT ANALYSIS
TABLE 3 RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS
TABLE 4 KEY BODIES WITH REGULATORY AUTHORITY OVER HEALTH CARE IN THE U.S.
TABLE 5 PRICE RANGE OF SOME MAJORLY USED X-RAY SYSTEMS
TABLE 6 PRICE RANGE OF SOME MAJORLY USED MRI SYSTEMS
TABLE 7 PRICE RANGE OF SOME MAJORLY USED ULTRASOUND SYSTEMS
TABLE 8 PRICE RANGE OF SOME MAJORLY USED CT SCANNERS
TABLE 9 PRICE RANGE OF SOME MAJORLY USED NUCLEAR IMAGING SYSTEMS
TABLE 10 U.S. HEALTHCARE INDUSTRY, BY DISEASE TYPE, $M (2019–2024)
TABLE 11 U.S. HEALTHCARE INDUSTRY, BY DISEASE TYPE, $M (2025–2030)
TABLE 12 U.S. HEALTHCARE INDUSTRY, BY PAYMENT MECHANISM, $B (2019–2024)
TABLE 13 U.S. HEALTHCARE INDUSTRY, BY PAYMENT MECHANISM, $B (2025–2030)
TABLE 14 U.S. HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, $M (2019–2024)
TABLE 15 U.S. HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, $M (2025–2030)
TABLE 16 U.S. HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, UNIT (2019–2024)
TABLE 17 U.S. HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, UNIT (2025–2030)
TABLE 18 U.S. HEALTHCARE INDUSTRY, BY IVD TECHNOLOGY, $M (2019–2024)
TABLE 19 U.S. HEALTHCARE INDUSTRY, BY IVD TECHNOLOGY, $M (2025–2030)
TABLE 20 U.S. HEALTHCARE INDUSTRY, BY CHANNEL, $B (2019–2024)
TABLE 21 U.S. HEALTHCARE INDUSTRY, BY CHANNEL, $B (2025–2030)
TABLE 22 U.S. HEALTHCARE INDUSTRY, BY HOSPITAL BED CAPACITY, $B (2019–2024)
TABLE 23 U.S. HEALTHCARE INDUSTRY, BY HOSPITAL BED CAPACITY, $B (2025–2030)
TABLE 24 U.S. HEALTHCARE INDUSTRY, BY PAYER TYPE, $B (2019–2024)
TABLE 25 U.S. HEALTHCARE INDUSTRY, BY PAYER TYPE, $B (2025–2030)
TABLE 26 U.S. HEALTHCARE INDUSTRY, BY PROVIDER TYPE, $B (2019–2024)
TABLE 27 U.S. HEALTHCARE INDUSTRY, BY PROVIDER TYPE, $B (2025–2030)
TABLE 28 U.S. HEALTHCARE INDUSTRY FOR SPECIALTY CARE, BY DISEASE TYPE, $M (2019–2024)
TABLE 29 U.S. HEALTHCARE INDUSTRY FOR SPECIALTY CARE, BY DISEASE TYPE, $M (2025–2030)
TABLE 30 U.S. HEALTHCARE INDUSTRY, BY CARE PATHWAY STAGE, $B (2019–2024)
TABLE 31 U.S. HEALTHCARE INDUSTRY, BY CARE PATHWAY STAGE, $B (2025–2030)
TABLE 32 U.S. HEALTHCARE INDUSTRY, BY DISEASE STAGE, $B (2019–2024)
TABLE 33 U.S. HEALTHCARE INDUSTRY, BY DISEASE STAGE, $B (2025–2030)
TABLE 34 GERMANY HEALTHCARE INDUSTRY, BY DISEASE TYPE, $M (2019–2024)
TABLE 35 GERMANY HEALTHCARE INDUSTRY, BY DISEASE TYPE, $M (2025–2030)
TABLE 36 GERMANY HEALTHCARE INDUSTRY, BY PAYMENT MECHANISM, $B (2019–2024)
TABLE 37 GERMANY HEALTHCARE INDUSTRY, BY PAYMENT MECHANISM, $B (2025–2030)
TABLE 38 GERMANY HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, $M (2019–2024)
TABLE 39 GERMANY HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, $M (2025–2030)
TABLE 40 GERMANY HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, UNIT (2019–2024)
TABLE 41 GERMANY HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, UNIT (2025–2030)
TABLE 42 GERMANY HEALTHCARE INDUSTRY, BY IVD TECHNOLOGY, $M (2019–2024)
TABLE 43 GERMANY HEALTHCARE INDUSTRY, BY IVD TECHNOLOGY, $M (2025–2030)
TABLE 44 GERMANY HEALTHCARE INDUSTRY, BY CHANNEL, $B (2019–2024)
TABLE 45 GERMANY HEALTHCARE INDUSTRY, BY CHANNEL, $B (2025–2030)
TABLE 46 GERMANY HEALTHCARE INDUSTRY, BY HOSPITAL BED CAPACITY, $B (2019–2024)
TABLE 47 GERMANY HEALTHCARE INDUSTRY, BY HOSPITAL BED CAPACITY, $B (2025–2030)
TABLE 48 GERMANY HEALTHCARE INDUSTRY, BY PROVIDER TYPE, $B (2019–2024)
TABLE 49 GERMANY HEALTHCARE INDUSTRY, BY PROVIDER TYPE, $B (2025–2030)
TABLE 50 GERMANY HEALTHCARE INDUSTRY FOR SPECIALTY CARE, BY DISEASE TYPE, $M (2019–2024)
TABLE 51 GERMANY HEALTHCARE INDUSTRY FOR SPECIALTY CARE, BY DISEASE TYPE, $M (2025–2030)
TABLE 52 GERMANY HEALTHCARE INDUSTRY, BY CARE PATHWAY STAGE, $B (2019–2024)
TABLE 53 GERMANY HEALTHCARE INDUSTRY, BY CARE PATHWAY STAGE, $B (2025–2030)
TABLE 54 GERMANY HEALTHCARE INDUSTRY, BY DISEASE STAGE TYPE, $B (2019–2024)
TABLE 55 GERMANY HEALTHCARE INDUSTRY, BY DISEASE STAGE TYPE, $B (2025–2030)
TABLE 56 U.K. HEALTHCARE INDUSTRY, BY DISEASE TYPE, $M (2019–2024)
TABLE 57 U.K. HEALTHCARE INDUSTRY, BY DISEASE TYPE, $M (2025–2030)
TABLE 58 U.K. HEALTHCARE INDUSTRY, BY PAYMENT MECHANISM, $B (2019–2024)
TABLE 59 U.K. HEALTHCARE INDUSTRY, BY PAYMENT MECHANISM, $B (2025–2030)
TABLE 60 U.K. HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, $M (2019–2024)
TABLE 61 U.K. HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, $M (2025–2030)
TABLE 62 U.K. HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, UNIT (2019–2024)
TABLE 63 U.K. HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, UNIT (2025–2030)
TABLE 64 U.K. HEALTHCARE INDUSTRY, BY IVD TECHNOLOGY, $M (2019–2024)
TABLE 65 U.K. HEALTHCARE INDUSTRY, BY IVD TECHNOLOGY, $M (2025–2030)
TABLE 66 U.K. HEALTHCARE INDUSTRY, BY CHANNEL, $B (2019–2024)
TABLE 67 U.K. HEALTHCARE INDUSTRY, BY CHANNEL, $B (2025–2030)
TABLE 68 U.K. HEALTHCARE INDUSTRY, BY HOSPITAL BED CAPACITY, $B (2019–2024)
TABLE 69 U.K. HEALTHCARE INDUSTRY, BY HOSPITAL BED CAPACITY, $B (2025–2030)
TABLE 70 U.K. HEALTHCARE INDUSTRY, BY PROVIDER TYPE, $B (2019–2024)
TABLE 71 U.K. HEALTHCARE INDUSTRY, BY PROVIDER TYPE, $B (2025–2030)
TABLE 72 U.K. HEALTHCARE INDUSTRY FOR SPECIALTY CARE, BY DISEASE TYPE, $M (2019–2024)
TABLE 73 U.K. HEALTHCARE INDUSTRY FOR SPECIALTY CARE, BY DISEASE TYPE, $M (2025–2030)
TABLE 74 U.K. HEALTHCARE INDUSTRY, BY CARE PATHWAY STAGE, $B (2019–2024)
TABLE 75 U.K. HEALTHCARE INDUSTRY, BY CARE PATHWAY STAGE, $B (2025–2030)
TABLE 76 U.K. HEALTHCARE INDUSTRY, BY DISEASE STAGE, $B (2019–2024)
TABLE 77 U.K. HEALTHCARE INDUSTRY, BY DISEASE STAGE TYPE, $B (2025–2030)
TABLE 78 FRANCE HEALTHCARE INDUSTRY, BY DISEASE TYPE, $M (2019–2024)
TABLE 79 FRANCE HEALTHCARE INDUSTRY, BY DISEASE TYPE, $M (2025–2030)
TABLE 80 FRANCE HEALTHCARE INDUSTRY, BY PAYMENT MECHANISM, $B (2019–2024)
TABLE 81 FRANCE HEALTHCARE INDUSTRY, BY PAYMENT MECHANISM, $B (2025–2030)
TABLE 82 FRANCE HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, $M (2019–2024)
TABLE 83 FRANCE HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, $M (2025–2030)
TABLE 84 FRANCE HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, UNIT (2019–2024)
TABLE 85 FRANCE HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, UNIT (2025–2030)
TABLE 86 FRANCE HEALTHCARE INDUSTRY, BY IVD TECHNOLOGY, $M (2019–2024)
TABLE 87 FRANCE HEALTHCARE INDUSTRY, BY IVD TECHNOLOGY, $M (2025–2030)
TABLE 88 FRANCE HEALTHCARE INDUSTRY, BY CHANNEL, $B (2019–2024)
TABLE 89 FRANCE HEALTHCARE INDUSTRY, BY CHANNEL, $B (2025–2030)
TABLE 90 FRANCE HEALTHCARE INDUSTRY, BY HOSPITAL BED CAPACITY, $B (2019–2024)
TABLE 91 FRANCE HEALTHCARE INDUSTRY, BY HOSPITAL BED CAPACITY, $B (2025–2030)
TABLE 92 FRANCE HEALTHCARE INDUSTRY, BY PROVIDER TYPE, $B (2019–2024)
TABLE 93 FRANCE HEALTHCARE INDUSTRY, BY PROVIDER TYPE, $B (2025–2030)
TABLE 94 FRANCE. HEALTHCARE INDUSTRY FOR SPECIALTY CARE, BY DISEASE TYPE, $M (2019–2024)
TABLE 95 FRANCE HEALTHCARE INDUSTRY FOR SPECIALTY CARE, BY DISEASE TYPE, $M (2025–2030)
TABLE 96 FRANCE HEALTHCARE INDUSTRY, BY CARE PATHWAY STAGE, $B (2019–2024)
TABLE 97 FRANCE HEALTHCARE INDUSTRY, BY CARE PATHWAY STAGE, $B (2025–2030)
TABLE 98 FRANCE HEALTHCARE INDUSTRY, BY DISEASE STAGE, $B (2019–2024)
TABLE 99 FRANCE HEALTHCARE INDUSTRY, BY DISEASE STAGE, $B (2025–2030)
TABLE 100 CHINA HEALTHCARE INDUSTRY, BY DISEASE TYPE, $M (2019–2024)
TABLE 101 CHINA HEALTHCARE INDUSTRY, BY DISEASE TYPE, $M (2025–2030)
TABLE 102 CHINA HEALTHCARE INDUSTRY, BY PAYMENT MECHANISM, $B (2019–2024)
TABLE 103 CHINA HEALTHCARE INDUSTRY, BY PAYMENT MECHANISM, $B (2025–2030)
TABLE 104 CHINA HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, $M (2019–2024)
TABLE 105 CHINA HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, $M (2025–2030)
TABLE 106 CHINA HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, UNIT (2019–2024)
TABLE 107 CHINA HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, UNIT (2019–2024)
TABLE 108 CHINA HEALTHCARE INDUSTRY, BY IVD TECHNOLOGY, $M (2019–2024)
TABLE 109 CHINA HEALTHCARE INDUSTRY, BY IVD TECHNOLOGY, $M (2025–2030)
TABLE 110 CHINA HEALTHCARE INDUSTRY, BY CHANNEL, $B (2019–2024)
TABLE 111 CHINA HEALTHCARE INDUSTRY, BY CHANNEL, $B (2025–2030)
TABLE 112 CHINA HEALTHCARE INDUSTRY, BY HOSPITAL BED CAPACITY, $B (2019–2024)
TABLE 113 CHINA HEALTHCARE INDUSTRY, BY HOSPITAL BED CAPACITY, $B (2025–2030)
TABLE 114 CHINA HEALTHCARE INDUSTRY, BY PROVIDER TYPE, $B (2019–2024)
TABLE 115 CHINA HEALTHCARE INDUSTRY, BY PROVIDER TYPE, $B (2025–2030)
TABLE 116 CHINA HEALTHCARE INDUSTRY FOR SPECIALTY CARE, BY DISEASE TYPE, $M (2019–2024)
TABLE 117 CHINA HEALTHCARE INDUSTRY FOR SPECIALTY CARE, BY DISEASE TYPE, $M (2025–2030)
TABLE 118 CHINA HEALTHCARE INDUSTRY, BY CARE PATHWAY STAGE, $B (2019–2024)
TABLE 119 CHINA HEALTHCARE INDUSTRY, BY CARE PATHWAY STAGE, $B (2025–2030)
TABLE 120 CHINA HEALTHCARE INDUSTRY, BY DISEASE STAGE, $B (2019–2024)
TABLE 121 CHINA HEALTHCARE INDUSTRY, BY DISEASE STAGE, $B (2025–2030)
TABLE 122 JAPAN HEALTHCARE INDUSTRY, BY DISEASE TYPE, $M (2019–2024)
TABLE 123 JAPAN HEALTHCARE INDUSTRY, BY DISEASE TYPE, $M (2025–2030)
TABLE 124 JAPAN HEALTHCARE INDUSTRY, BY PAYMENT MECHANISM, $B (2019–2024)
TABLE 125 JAPAN HEALTHCARE INDUSTRY, BY PAYMENT MECHANISM, $B (2025–2030)
TABLE 126 JAPAN HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, $M (2019–2024)
TABLE 127 JAPAN HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, $M (2025–2030)
TABLE 128 JAPAN HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, UNIT (2019–2024)
TABLE 129 JAPAN HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, UNIT (2025–2030)
TABLE 130 JAPAN HEALTHCARE INDUSTRY, BY IVD TECHNOLOGY, $M (2019–2024)
TABLE 131 JAPAN HEALTHCARE INDUSTRY, BY IVD TECHNOLOGY, $M (2025–2030)
TABLE 132 JAPAN HEALTHCARE INDUSTRY, BY CHANNEL, $B (2019–2024)
TABLE 133 JAPAN HEALTHCARE INDUSTRY, BY CHANNEL, $B (2025–2030)
TABLE 134 JAPAN HEALTHCARE INDUSTRY, BY HOSPITAL BED CAPACITY, $B (2019–2024)
TABLE 135 JAPAN HEALTHCARE INDUSTRY, BY HOSPITAL BED CAPACITY, $B (2025–2030)
TABLE 136 JAPAN HEALTHCARE INDUSTRY, BY PROVIDER TYPE, $B (2019–2024)
TABLE 137 JAPAN HEALTHCARE INDUSTRY, BY PROVIDER TYPE, $B (2025–2030)
TABLE 138 JAPAN HEALTHCARE INDUSTRY FOR SPECIALTY CARE, BY DISEASE TYPE, $M (2019–2024)
TABLE 139 JAPAN HEALTHCARE INDUSTRY FOR SPECIALTY CARE, BY DISEASE TYPE, $M (2025–2030)
TABLE 140 JAPAN HEALTHCARE INDUSTRY, BY CARE PATHWAY STAGE, $B (2019–2024)
TABLE 141 JAPAN HEALTHCARE INDUSTRY, BY CARE PATHWAY STAGE, $B (2025–2030)
TABLE 142 JAPAN HEALTHCARE INDUSTRY, BY DISEASE STAGE, $B (2019–2024)
TABLE 143 JAPAN HEALTHCARE INDUSTRY, BY DISEASE STAGE, $B (2025–2030)
TABLE 144 SINGAPORE HEALTHCARE INDUSTRY, BY DISEASE TYPE, $M (2019–2024)
TABLE 145 SINGAPORE HEALTHCARE INDUSTRY, BY DISEASE TYPE, $M (2025–2030)
TABLE 146 SINGAPORE HEALTHCARE INDUSTRY, BY PAYMENT MECHANISM, $B (2019–2024)
TABLE 147 SINGAPORE HEALTHCARE INDUSTRY, BY PAYMENT MECHANISM, $B (2025–2030)
TABLE 148 SINGAPORE HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, $M (2019–2024)
TABLE 149 SINGAPORE HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, $M (2025–2030)
TABLE 150 SINGAPORE HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, UNIT (2019–2024)
TABLE 151 SINGAPORE HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, UNIT (2025–2030)
TABLE 152 SINGAPORE HEALTHCARE INDUSTRY, BY IVD TECHNOLOGY, $M (2019–2024)
TABLE 153 SINGAPORE HEALTHCARE INDUSTRY, BY IVD TECHNOLOGY, $M (2025–2030)
TABLE 154 SINGAPORE HEALTHCARE INDUSTRY, BY CHANNEL, $B (2019–2024)
TABLE 155 SINGAPORE HEALTHCARE INDUSTRY, BY CHANNEL, $B (2025–2030)
TABLE 156 SINGAPORE HEALTHCARE INDUSTRY, BY HOSPITAL BED CAPACITY, $B (2019–2024)
TABLE 157 SINGAPORE HEALTHCARE INDUSTRY, BY HOSPITAL BED CAPACITY, $B (2025–2030)
TABLE 158 SINGAPORE HEALTHCARE INDUSTRY, BY PROVIDER TYPE, $B (2019–2024)
TABLE 159 SINGAPORE HEALTHCARE INDUSTRY, BY PROVIDER TYPE, $B (2025–2030)
TABLE 160 SINGAPORE HEALTHCARE INDUSTRY FOR SPECIALTY CARE, BY DISEASE TYPE, $M (2019–2024)
TABLE 161 SINGAPORE HEALTHCARE INDUSTRY FOR SPECIALTY CARE, BY DISEASE TYPE, $M (2025–2030)
TABLE 162 SINGAPORE HEALTHCARE INDUSTRY, BY CARE PATHWAY STAGE, $B (2019–2024)
TABLE 163 SINGAPORE HEALTHCARE INDUSTRY, BY CARE PATHWAY STAGE, $B (2025–2030)
TABLE 164 SINGAPORE HEALTHCARE INDUSTRY, BY DISEASE STAGE, $B (2019–2024)
TABLE 165 SINGAPORE HEALTHCARE INDUSTRY, BY DISEASE STAGE, $B (2025–2030)
TABLE 166 GENERAL ELECTRIC COMPANY – AT A GLANCE
TABLE 167 GENERAL ELECTRIC COMPANY – KEY FINANCIAL SUMMARY
TABLE 168 KONINKLIJKE PHILIPS N.V. – AT A GLANCE
TABLE 169 KONINKLIJKE PHILIPS N.V. – KEY FINANCIAL SUMMARY
TABLE 170 SIEMENS AG – AT A GLANCE
TABLE 171 SIEMENS AG – KEY FINANCIAL SUMMARY
TABLE 172 CANON MEDICAL SYSTEMS CORPORATION – AT A GLANCE
TABLE 173 CANON MEDICAL SYSTEMS CORPORATION – KEY FINANCIAL SUMMARY
TABLE 174 SHIMADZU CORPORATION – AT A GLANCE
TABLE 175 SHIMADZU CORPORATION – KEY FINANCIAL SUMMARY
TABLE 176 CARESTREAM HEALTH INC. – AT A GLANCE
TABLE 177 ESAOTE S.P.A. – AT A GLANCE
TABLE 178 FUJIFILM HOLDINGS CORPORATION – AT A GLANCE
TABLE 179 FUJIFILM HOLDINGS CORPORATION – KEY FINANCIAL SUMMARY
TABLE 180 SAMSUNG ELECTRONICS CO. LTD. – AT A GLANCE
TABLE 181 SAMSUNG ELECTRONICS CO. LTD. – KEY FINANCIAL SUMMARY
TABLE 182 HOLOGIC INC. – AT A GLANCE
TABLE 183 HOLOGIC INC. – KEY FINANCIAL SUMMARY
TABLE 184 BIOMÉRIEUX S.A. – AT A GLANCE
TABLE 185 BIOMÉRIEUX S.A. – KEY FINANCIAL SUMMARY
TABLE 186 BIO-RAD LABORATORIES INC. – AT A GLANCE
TABLE 187 BIO-RAD LABORATORIES INC. – KEY FINANCIAL SUMMARY
TABLE 188 THERMO FISHER SCIENTIFIC INC. – AT A GLANCE
TABLE 189 THERMO FISHER SCIENTIFIC INC. – KEY FINANCIAL SUMMARY
TABLE 190 BECTON, DICKINSON AND COMPANY – AT A GLANCE
TABLE 191 BECTON, DICKINSON AND COMPANY – KEY FINANCIAL SUMMARY
TABLE 192 DANAHER CORPORATION – AT A GLANCE
TABLE 193 DANAHER CORPORATION – KEY FINANCIAL SUMMARY
TABLE 194 ABBOTT LABORATORIES – AT A GLANCE
TABLE 195 ABBOTT LABORATORIES – KEY FINANCIAL SUMMARY
TABLE 196 SIEMENS AG – AT A GLANCE
TABLE 197 SIEMENS AG – KEY FINANCIAL SUMMARY
TABLE 198 QIAGEN N.V. - AT A GLANCE
TABLE 199 QIAGEN N.V. – KEY FINANCIAL SUMMARY
TABLE 200 DIASORIN S.P.A. - AT A GLANCE
TABLE 201 DIASORIN S.P.A. – KEY FINANCIAL SUMMARY
TABLE 202 ORTHO-CLINICAL DIAGNOSTICS INC. - AT A GLANCE
TABLE 203 F. HOFFMANN-LA ROCHE LTD. – AT A GLANCE
TABLE 204 F. HOFFMANN-LA ROCHE LTD. – KEY FINANCIAL SUMMARY
TABLE 205 AGILENT TECHNOLOGIES INC. – AT A GLANCE
TABLE 206 AGILENT TECHNOLOGIES INC. – KEY FINANCIAL SUMMARY
LIST OF FIGURES
FIG 1 RESEARCH SCOPE
FIG 2 RESEARCH METHODOLOGY
FIG 3 SPLIT OF PRIMARY AND SECONDARY RESEARCH, BY COUNTRY
FIG 4 BREAKDOWN OF PRIMARY RESEARCH, BY COUNTRY
FIG 5 BREAKDOWN OF PRIMARY RESEARCH, BY INDUSTRY PARTICIPANT
FIG 6 BREAKDOWN OF PRIMARY RESEARCH, BY COMPANY TYPE
FIG 7 DATA TRIANGULATION APPROACH
FIG 8 EXECUTIVE SUMMARY
FIG 9 GDP OF SOME MAJOR COUNTRIES, $M (2011 & 2017)
FIG 10 HEALTHCARE EXPENDITURE AS PERCENTAGE OF GDP (2011 & 2017)
FIG 11 BARGAINING POWER OF BUYERS
FIG 12 BARGAINING POWER OF SUPPLIERS
FIG 13 INTENSITY OF RIVALRY
FIG 14 THREAT OF NEW ENTRANTS
FIG 15 THREAT OF SUBSTITUTES
FIG 16 PESTLE ANALYSIS FOR THE U.S.
FIG 17 PESTLE ANALYSIS FOR THE U.K.
FIG 18 PESTLE ANALYSIS FOR FRANCE
FIG 19 PESTLE ANALYSIS FOR GERMANY
FIG 20 PESTLE ANALYSIS FOR CHINA
FIG 21 PESTLE ANALYSIS FOR JAPAN
FIG 22 PESTLE ANALYSIS FOR SINGAPORE
FIG 23 U.S. HEALTHCARE INDUSTRY SNAPSHOT
FIG 24 U.S. HEALTHCARE INDUSTRY, BY DISEASE TYPE, $M (2019–2030)
FIG 25 U.S. HEALTHCARE INDUSTRY, BY PAYMENT MECHANISM, $B (2019–2030)
FIG 26 U.S. HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, $M (2019–2030)
FIG 27 U.S. HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, UNIT (2019–2030)
FIG 28 U.S. HEALTHCARE INDUSTRY, BY IVD TECHNOLOGY, $M (2019–2030)
FIG 29 U.S. HEALTHCARE INDUSTRY, BY CHANNEL, $B (2019–2030)
FIG 30 U.S. HEALTHCARE INDUSTRY, BY HOSPITAL BED CAPACITY, $B (2019–2030)
FIG 31 U.S. HEALTHCARE INDUSTRY, BY PAYER TYPE, $B (2019–2030)
FIG 32 U.S. HEALTHCARE INDUSTRY, BY PROVIDER TYPE, $B (2019–2030)
FIG 33 U.S. HEALTHCARE INDUSTRY FOR SPECIALTY CARE, BY DISEASE TYPE, $M (2019–2030)
FIG 34 U.S. HEALTHCARE INDUSTRY, BY CARE PATHWAY STAGE, $B (2019–2030)
FIG 35 U.S. HEALTHCARE INDUSTRY, BY DISEASE STAGE, $B (2019–2030)
FIG 36 GERMANY HEALTHCARE INDUSTRY SNAPSHOT
FIG 37 GERMANY HEALTHCARE INDUSTRY, BY DISEASE TYPE, $M (2019–2030)
FIG 38 GERMANY HEALTHCARE INDUSTRY, BY PAYMENT MECHANISM, $B (2019–2030)
FIG 39 GERMANY HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, $M (2019–2030)
FIG 40 GERMANY HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, UNIT (2019–2030)
FIG 41 GERMANY HEALTHCARE INDUSTRY, BY IVD TECHNOLOGY, $M (2019–2030)
FIG 42 GERMANY HEALTHCARE INDUSTRY, BY CHANNEL, $B (2019–2030)
FIG 43 GERMANY HEALTHCARE INDUSTRY, BY HOSPITAL BED CAPACITY, $B (2019–2030)
FIG 44 GERMANY HEALTHCARE INDUSTRY, BY PROVIDER TYPE, $B (2019–2030)
FIG 45 GERMANY HEALTHCARE INDUSTRY FOR SPECIALTY CARE, BY DISEASE TYPE, $M (2019–2030)
FIG 46 GERMANY HEALTHCARE INDUSTRY, BY CARE PATHWAY STAGE, $B (2019–2030)
FIG 47 GERMANY HEALTHCARE INDUSTRY, BY DISEASE STAGE, $B (2019–2030)
FIG 48 U.K. HEALTHCARE INDUSTRY SNAPSHOT
FIG 49 U.K. HEALTHCARE INDUSTRY, BY DISEASE TYPE, $M (2019–2030)
FIG 50 U.K. HEALTHCARE INDUSTRY, BY PAYMENT MECHANISM, $B (2019–2030)
FIG 51 U.K. HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, $M (2019–2030)
FIG 52 U.K. HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, UNIT (2019–2030)
FIG 53 U.K. HEALTHCARE INDUSTRY, BY IVD TECHNOLOGY, $M (2019–2030)
FIG 54 U.K. HEALTHCARE INDUSTRY, BY CHANNEL, $B (2019–2030)
FIG 55 U.K. HEALTHCARE INDUSTRY, BY HOSPITAL BED CAPACITY, $B (2019–2030)
FIG 56 U.K. HEALTHCARE INDUSTRY, BY PROVIDER TYPE, $B (2019–2030)
FIG 57 U.K. HEALTHCARE INDUSTRY FOR SPECIALTY CARE, BY DISEASE TYPE, $M (2019–2030)
FIG 58 U.K. HEALTHCARE INDUSTRY, BY CARE PATHWAY STAGE, $B (2019–2030)
FIG 59 U.K. HEALTHCARE INDUSTRY, BY DISEASE STAGE, $B (2019–2030)
FIG 60 FRANCE HEALTHCARE INDUSTRY SNAPSHOT
FIG 61 FRANCE HEALTHCARE INDUSTRY, BY DISEASE TYPE, $M (2019–2030)
FIG 62 FRANCE HEALTHCARE INDUSTRY, BY PAYMENT MECHANISM, $B (2019–2030)
FIG 63 FRANCE HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, $M (2019–2030)
FIG 64 FRANCE HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, UNIT (2019–2030)
FIG 65 FRANCE HEALTHCARE INDUSTRY, BY IVD TECHNOLOGY, $M (2019–2030)
FIG 66 FRANCE HEALTHCARE INDUSTRY, BY CHANNEL, $B (2019–2030)
FIG 67 FRANCE HEALTHCARE INDUSTRY, BY HOSPITAL BED CAPACITY, $B (2019–2030)
FIG 68 FRANCE HEALTHCARE INDUSTRY, BY PROVIDER TYPE, $B (2019–2030)
FIG 69 FRANCE HEALTHCARE INDUSTRY FOR SPECIALTY CARE, BY DISEASE TYPE, $M (2019–2030)
FIG 70 FRANCE HEALTHCARE INDUSTRY, BY CARE PATHWAY STAGE, $B (2019–2030)
FIG 71 FRANCE HEALTHCARE INDUSTRY, BY DISEASE STAGE, $B (2019–2030)
FIG 72 CHINA HEALTHCARE INDUSTRY SNAPSHOT
FIG 73 CHINA HEALTHCARE INDUSTRY, BY DISEASE TYPE, $M (2019–2030)
FIG 74 CHINA HEALTHCARE INDUSTRY, BY PAYMENT MECHANISM, $B (2019–2030)
FIG 75 CHINA HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, $M (2019–2030)
FIG 76 CHINA HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, UNIT (2019–2030)
FIG 77 CHINA HEALTHCARE INDUSTRY, BY IVD TECHNOLOGY, $M (2019–2030)
FIG 78 CHINA HEALTHCARE INDUSTRY, BY CHANNEL, $B (2019–2030)
FIG 79 CHINA HEALTHCARE INDUSTRY, BY HOSPITAL BED CAPACITY, $B (2019–2030)
FIG 80 CHINA HEALTHCARE INDUSTRY, BY PROVIDER TYPE, $B (2019–2030)
FIG 81 CHINA HEALTHCARE INDUSTRY FOR SPECIALTY CARE, BY DISEASE TYPE, $M (2019–2030)
FIG 82 CHINA HEALTHCARE INDUSTRY, BY CARE PATHWAY STAGE, $B (2019–2030)
FIG 83 CHINA HEALTHCARE INDUSTRY, BY DISEASE STAGE, $B (2019–2030)
FIG 84 JAPAN HEALTHCARE INDUSTRY SNAPSHOT
FIG 85 JAPAN HEALTHCARE INDUSTRY, BY DISEASE TYPE, $M (2019–2030)
FIG 86 JAPAN HEALTHCARE INDUSTRY, BY PAYMENT MECHANISM, $B (2019–2030)
FIG 87 JAPAN HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, $M (2019–2030)
FIG 88 JAPAN HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, UNIT (2019–2030)
FIG 89 JAPAN HEALTHCARE INDUSTRY, BY IVD TECHNOLOGY, $M (2019–2030)
FIG 90 JAPAN HEALTHCARE INDUSTRY, BY CHANNEL, $B (2019–2030)
FIG 91 JAPAN HEALTHCARE INDUSTRY, BY HOSPITAL BED CAPACITY, $B (2019–2030)
FIG 92 JAPAN HEALTHCARE INDUSTRY, BY PROVIDER TYPE, $B (2019–2030)
FIG 93 JAPAN HEALTHCARE INDUSTRY FOR SPECIALTY CARE, BY DISEASE TYPE, $M (2019–2030)
FIG 94 JAPAN HEALTHCARE INDUSTRY, BY CARE PATHWAY STAGE, $B (2019–2030)
FIG 95 JAPAN HEALTHCARE INDUSTRY, BY DISEASE STAGE, $B (2019–2030)
FIG 96 SINGAPORE HEALTHCARE INDUSTRY SNAPSHOT
FIG 97 SINGAPORE HEALTHCARE INDUSTRY, BY DISEASE TYPE, $M (2019–2030)
FIG 98 SINGAPORE HEALTHCARE INDUSTRY, BY PAYMENT MECHANISM, $B (2019–2030)
FIG 99 SINGAPORE HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, $M (2019–2030)
FIG 100 SINGAPORE HEALTHCARE INDUSTRY, BY DIAGNOSTIC EQUIPMENT TYPE, UNIT (2019–2030)
FIG 101 SINGAPORE HEALTHCARE INDUSTRY, BY IVD TECHNOLOGY, $M (2019–2030)
FIG 102 SINGAPORE HEALTHCARE INDUSTRY, BY CHANNEL, $B (2019–2030)
FIG 103 SINGAPORE HEALTHCARE INDUSTRY, BY HOSPITAL BED CAPACITY, $B (2019–2030)
FIG 104 SINGAPORE HEALTHCARE INDUSTRY, BY PROVIDER TYPE, $B (2019–2030)
FIG 105 SINGAPORE HEALTHCARE INDUSTRY FOR SPECIALTY CARE, BY DISEASE TYPE, $M (2019–2030)
FIG 106 SINGAPORE HEALTHCARE INDUSTRY, BY CARE PATHWAY STAGE, $B (2019–2030)
FIG 107 SINGAPORE HEALTHCARE INDUSTRY, BY DISEASE STAGE, $B (2019–2030)
FIG 108 MARKET SHARE ANALYSIS OF DIAGNOSTIC IMAGING EQUIPMENT IN THE U.S.
FIG 109 MARKET SHARE ANALYSIS OF DIAGNOSTIC IMAGING EQUIPMENT IN GERMANY
FIG 110 MARKET SHARE ANALYSIS OF DIAGNOSTIC IMAGING EQUIPMENT IN CHINA
FIG 111 MARKET SHARE ANALYSIS OF IVD IN THE U.S.
FIG 112 MARKET SHARE ANALYSIS OF IVD IN GERMANY
FIG 113 MARKET SHARE ANALYSIS OF IVD IN CHINA
FIG 114 GENERAL ELECTRIC COMPANY – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)
FIG 115 KONINKLIJKE PHILIPS N.V. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)
FIG 116 SIEMENS AG – REVENUE SPLIT BY DIVISION AND GEOGRAPHY (2023)
FIG 117 CANON MEDICAL SYSTEMS CORPORATION – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)
FIG 118 SHIMADZU CORPORATION – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)
FIG 119 FUJIFILM HOLDINGS CORPORATION – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)
FIG 120 SAMSUNG ELECTRONICS CO. LTD. – REVENUE SPLIT BY BUSINESS DIVISION AND GEOGRAPHY (2023)
FIG 121 HOLOGIC INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)
FIG 122 BIOMÉRIEUX S.A. – REVENUE SPLIT BY APPLICATION AND GEOGRAPHY (2023)
FIG 123 BIO-RAD LABORATORIES INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)
FIG 124 THERMO FISHER SCIENTIFIC INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)
FIG 125 BECTON, DICKINSON AND COMPANY – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)
FIG 126 DANAHER CORPORATION – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)
FIG 127 ABBOTT LABORATORIES – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)
FIG 128 SIEMENS AG – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)
FIG 129 QIAGEN N.V. – REVENUE SPLIT BY GEOGRAPHY AND CONSUMER CLASS (2023)
FIG 130 DIASORIN S.P.A. – REVENUE SPLIT BY GEOGRAPHY (2023)
FIG 131 F. HOFFMANN-LA ROCHE LTD. – REVENUE SPLIT BY DIVISION AND GEOGRAPHY (2023)
FIG 132 AGILENT TECHNOLOGIES INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)
Want a report tailored exactly to your business strategy?
Request CustomizationWant an insight-rich discussion with the report author?
Speak to Analyst
Our dedication to providing the most-accurate market information has earned us verification by Dun & Bradstreet (D&B). We strive for quality checking of the highest level to enable data-driven decision making for you
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
With 24/7 research support, we ensure that the wheels of your business never stop turning. Don’t let time stand in your way. Get all your queries answered with a simple phone call or email, as and when required
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws